Actinium Pharmaceuticals Class Action Lawsuit

Actinium Pharmaceuticals is facing a class action lawsuit initiated by The Gross Law Firm on behalf of shareholders who purchased shares between October 31, 2022, and August 2, 2024. The lawsuit alleges that Actinium Pharmaceuticals issued materially false and/or misleading statements and failed to disclose that its data from the Phase 3 Sierra trial was unlikely to satisfy the United States — Food and Drug Administration's guidelines for the acceptance and approval of its targeted radiotherapy, Iomab-B BLA. Furthermore, additional analyses provided to the United States — Food and Drug Administration to mitigate poor Overall Survival data were also unlikely to satisfy the guidelines, potentially leading to the refusal of review or approval of the Iomab-B BLA. The deadline for shareholders to seek lead plaintiff appointment is May 27, 2025.